Compare Torrent Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs AJANTA PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA AJANTA PHARMA TORRENT PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 56.5 22.3 253.8% View Chart
P/BV x 6.8 3.8 176.6% View Chart
Dividend Yield % 0.8 0.9 82.3%  

Financials

 TORRENT PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
AJANTA PHARMA
Mar-19
TORRENT PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5501,422 109.0%   
Low Rs1,144898 127.4%   
Sales per share (Unadj.) Rs354.7233.5 151.9%  
Earnings per share (Unadj.) Rs40.144.0 91.2%  
Cash flow per share (Unadj.) Rs64.252.2 123.1%  
Dividends per share (Unadj.) Rs14.009.00 155.6%  
Dividend yield (eoy) %1.00.8 134.0%  
Book value per share (Unadj.) Rs273.1255.1 107.1%  
Shares outstanding (eoy) m169.2288.02 192.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.85.0 76.5%   
Avg P/E ratio x33.626.4 127.4%  
P/CF ratio (eoy) x21.022.2 94.3%  
Price / Book Value ratio x4.94.5 108.4%  
Dividend payout %34.920.5 170.7%   
Avg Mkt Cap Rs m227,897102,081 223.3%   
No. of employees `00014.76.8 216.2%   
Total wages/salary Rs m11,3534,307 263.6%   
Avg. sales/employee Rs Th4,083.03,022.6 135.1%   
Avg. wages/employee Rs Th772.3633.4 121.9%   
Avg. net profit/employee Rs Th461.3569.1 81.1%   
INCOME DATA
Net Sales Rs m60,02120,554 292.0%  
Other income Rs m2,988211 1,417.6%   
Total revenues Rs m63,00920,765 303.4%   
Gross profit Rs m13,4935,664 238.2%  
Depreciation Rs m4,086721 566.9%   
Interest Rs m3,08512 26,593.1%   
Profit before tax Rs m9,3105,143 181.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5291,273 198.6%   
Profit after tax Rs m6,7813,870 175.2%  
Gross profit margin %22.527.6 81.6%  
Effective tax rate %27.224.8 109.7%   
Net profit margin %11.318.8 60.0%  
BALANCE SHEET DATA
Current assets Rs m52,62311,812 445.5%   
Current liabilities Rs m52,0223,776 1,377.5%   
Net working cap to sales %1.039.1 2.6%  
Current ratio x1.03.1 32.3%  
Inventory Days Days12077 154.5%  
Debtors Days Days7682 93.4%  
Net fixed assets Rs m85,01614,398 590.5%   
Share capital Rs m846175 482.4%   
"Free" reserves Rs m45,37622,277 203.7%   
Net worth Rs m46,22222,452 205.9%   
Long term debt Rs m41,1157 622,948.5%   
Total assets Rs m142,43226,962 528.3%  
Interest coverage x4.0444.3 0.9%   
Debt to equity ratio x0.90 302,594.7%  
Sales to assets ratio x0.40.8 55.3%   
Return on assets %6.914.4 48.1%  
Return on equity %14.717.2 85.1%  
Return on capital %14.223.0 61.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58010,682 136.5%   
Fx outflow Rs m3,6002,102 171.3%   
Net fx Rs m10,9808,580 128.0%   
CASH FLOW
From Operations Rs m8,9423,748 238.6%  
From Investments Rs m-47,070-2,228 2,112.6%  
From Financial Activity Rs m34,174-1,475 -2,317.5%  
Net Cashflow Rs m-3,65545 -8,086.3%  

Share Holding

Indian Promoters % 71.5 73.8 96.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 1.6 452.9%  
FIIs % 12.6 7.6 165.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.0 51.8%  
Shareholders   26,511 20,968 126.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON   FULFORD INDIA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 6, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS